Información de Merck & Co Inc, dividendo de Merck & Co Inc, actividades de los accionistas y más

Más Datos de Merck & Co Inc Compañía

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.

Información de Merck & Co Inc



Símbolo de cotizaciónMRK

Nombre de la empresaMerck & Co Inc

Fecha de salida a bolsaFeb 06, 2077

Director ejecutivoDavis (Robert M)

Número de empleados75000

Tipo de seguridadOrdinary Share

Fin del año fiscalFeb 06

Dirección126 East Lincoln Avenue

CiudadRAHWAY

Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE

PaísUnited States of America

Código postal07065

Teléfono19087404000

Sitio Webhttps://www.merck.com/

Símbolo de cotizaciónMRK

Fecha de salida a bolsaFeb 06, 2077

Director ejecutivoDavis (Robert M)

Ejecutivos de Merck & Co Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Robert M. (Rob) Davis

Chairman of the Board, President, Chief Executive Officer

443.60K

-10.69%

Mr. Sanat Chattopadhyay

Executive Vice President and President - Merck Manufacturing Division

199.21K

--

Dr. Dean Y. Li, M.D., Ph.D.

Executive Vice President, President - Merck Research Laboratories

92.03K

-8.72%

Ms. Jennifer L. Zachary

Executive Vice President, General Counsel

68.92K

+5.68%

Mr. Chirfi Guindo

Senior Vice President, Chief Marketing Officer - Human Health

55.21K

-72.45%

Mr. Joseph Edward Romanelli

Senior Vice President, President - MSD International Human Health

28.61K

+19.93%

Ms. Patricia F. Russo

Independent Director

13.15K

--

Mr. Thomas Henry (Tom) Glocer, J.D.

Lead Independent Director

5.10K

--

Mr. Inge G. Thulin

Independent Director

2.93K

--

Ms. Pamela J. Craig

Independent Director

1.72K

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Robert M. (Rob) Davis

Chairman of the Board, President, Chief Executive Officer

443.60K

-10.69%

Mr. Sanat Chattopadhyay

Executive Vice President and President - Merck Manufacturing Division

199.21K

--

Dr. Dean Y. Li, M.D., Ph.D.

Executive Vice President, President - Merck Research Laboratories

92.03K

-8.72%

Ms. Jennifer L. Zachary

Executive Vice President, General Counsel

68.92K

+5.68%

Mr. Chirfi Guindo

Senior Vice President, Chief Marketing Officer - Human Health

55.21K

-72.45%

Mr. Joseph Edward Romanelli

Senior Vice President, President - MSD International Human Health

28.61K

+19.93%

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de abr

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Por negocioUSD

Nombre

Ganancia

Proporción

Oncology-Keytruda

31.64B

48.67%

Vaccines -Gardasil/Gardasil

5.23B

8.05%

Animal Health-Livestock

3.90B

5.99%

Other pharmaceutical

2.92B

4.49%

Animal Health-Companion Animals

2.46B

3.78%

Otro

18.86B

29.02%

Por regiónUSD

Nombre

Ganancia

Proporción

United States

36.51B

56.16%

Europe, Middle East and Africa

14.58B

22.43%

Latin America

3.41B

5.25%

Asia Pacific (Other than China and Japan)

2.98B

4.59%

Other

2.88B

4.43%

Otro

4.65B

7.15%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Oncology-Keytruda

31.64B

48.67%

Vaccines -Gardasil/Gardasil

5.23B

8.05%

Animal Health-Livestock

3.90B

5.99%

Other pharmaceutical

2.92B

4.49%

Animal Health-Companion Animals

2.46B

3.78%

Otro

18.86B

29.02%

Estadísticas de accionistas

Actualizado: hace 14 horas

Accionistas

Tipos de accionistas

Accionistas

Proporción

Vanguard Capital Management, LLC

6.52%

BlackRock Institutional Trust Company, N.A.

5.51%

State Street Investment Management (US)

4.86%

Wellington Management Company, LLP

3.50%

Vanguard Portfolio Management, LLC

2.73%

Otro

76.88%

Accionistas

Proporción

Vanguard Capital Management, LLC

6.52%

BlackRock Institutional Trust Company, N.A.

5.51%

State Street Investment Management (US)

4.86%

Wellington Management Company, LLP

3.50%

Vanguard Portfolio Management, LLC

2.73%

Otro

76.88%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

52.27%

Investment Advisor/Hedge Fund

27.18%

Research Firm

3.05%

Pension Fund

2.68%

Bank and Trust

2.22%

Sovereign Wealth Fund

1.63%

Hedge Fund

1.38%

Insurance Company

0.70%

Family Office

0.12%

Otro

8.77%

Participación institucional



Actualizado: dom., 5 de abr

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2026Q1

5687

2.01B

81.41%

-10.60M

2025Q4

5433

1.99B

80.26%

-56.89M

2025Q3

5358

2.02B

81.35%

-45.75M

2025Q2

5398

2.02B

80.82%

-16.42M

2025Q1

5446

2.05B

81.47%

-3.32M

2024Q4

5410

2.04B

80.88%

+11.87M

2024Q3

5200

2.01B

79.47%

-7.96M

2024Q2

5181

2.01B

79.28%

-4.86M

2024Q1

5154

2.00B

78.88%

-6.10M

2023Q4

5065

1.99B

78.60%

+584.81K

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

BlackRock Institutional Trust Company, N.A.

136.21M

5.51%

-4.94M

-3.50%

Dec 31, 2025

State Street Investment Management (US)

120.04M

4.86%

+1.86M

+1.57%

Dec 31, 2025

Wellington Management Company, LLP

86.44M

3.5%

+11.16M

+14.82%

Dec 31, 2025

Geode Capital Management, L.L.C.

60.05M

2.43%

+249.11K

+0.42%

Dec 31, 2025

Charles Schwab Investment Management, Inc.

48.56M

1.96%

-5.14M

-9.56%

Dec 31, 2025

Norges Bank Investment Management (NBIM)

37.98M

1.54%

+1.87M

+5.18%

Dec 31, 2025

Fidelity Management & Research Company LLC

33.75M

1.36%

+6.13M

+22.20%

Dec 31, 2025

Fisher Investments

24.87M

1.01%

+805.20K

+3.35%

Dec 31, 2025

ETFs relacionados



Actualizado: sáb., 6 de dic

Nombre

Proporción

VanEck Pharmaceutical ETF

16.09%

FT Vest DJIA Dogs 10 Target Income ETF

10.79%

First Trust NASDAQ Pharmaceuticals ETF

7.94%

Invesco Dow Jones Industrial Average Dividend ETF

6.94%

First Trust Morningstar Dividend Leaders Index Fund

5.39%

Coastal Compass 100 ETF

5.13%

Invesco Pharmaceuticals ETF

4.96%

VanEck Morningstar Wide Moat Value ETF

4.73%

Vaneck Durable High Dividend ETF

4.65%

Franklin Income Focus ETF

4.56%

VanEck Pharmaceutical ETF

Proporción16.09%

FT Vest DJIA Dogs 10 Target Income ETF

Proporción10.79%

First Trust NASDAQ Pharmaceuticals ETF

Proporción7.94%

Invesco Dow Jones Industrial Average Dividend ETF

Proporción6.94%

First Trust Morningstar Dividend Leaders Index Fund

Proporción5.39%

Coastal Compass 100 ETF

Proporción5.13%

Invesco Pharmaceuticals ETF

Proporción4.96%

VanEck Morningstar Wide Moat Value ETF

Proporción4.73%

Vaneck Durable High Dividend ETF

Proporción4.65%

Franklin Income Focus ETF

Proporción4.56%

Dividendos



Un total de 28.91B USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Jan 27, 2026

MRK.NB Interim Cash Dividend of gross USD 0.85 paid on Apr 07, 2026 going ex on Mar 16, 2026

Mar 16, 2026

Apr 07, 2026

Mar 16, 2026

Nov 18, 2025

MRK.NB Interim Cash Dividend of gross USD 0.85 paid on Jan 08, 2026 going ex on Dec 15, 2025

Dec 15, 2025

Jan 08, 2026

Dec 15, 2025

Jul 22, 2025

MRK.NB Final Cash Dividend of gross USD 0.81 paid on Oct 07, 2025 going ex on Sep 15, 2025

Sep 15, 2025

Oct 07, 2025

Sep 15, 2025

May 27, 2025

MRK.NB Interim Cash Dividend of gross USD 0.81 paid on Jul 08, 2025 going ex on Jun 16, 2025

Jun 16, 2025

Jul 08, 2025

Jun 16, 2025

Jan 28, 2025

MRK.NB Interim Cash Dividend of gross USD 0.81 paid on Apr 07, 2025 going ex on Mar 17, 2025

Mar 17, 2025

Apr 07, 2025

Mar 17, 2025

Nov 19, 2024

MRK.NB Final Cash Dividend of gross USD 0.81 paid on Jan 08, 2025 going ex on Dec 16, 2024

Dec 16, 2024

Jan 08, 2025

Dec 16, 2024

Jul 23, 2024

MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Oct 07, 2024 going ex on Sep 16, 2024

Sep 16, 2024

Oct 07, 2024

Sep 16, 2024

May 29, 2024

MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Jul 08, 2024 going ex on Jun 17, 2024

Jun 17, 2024

Jul 08, 2024

Jun 17, 2024

Jan 23, 2024

MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Apr 05, 2024 going ex on Mar 14, 2024

Mar 15, 2024

Apr 05, 2024

Mar 14, 2024

Nov 28, 2023

MRK.NB Final Cash Dividend of gross USD 0.77 paid on Jan 08, 2024 going ex on Dec 14, 2023

Dec 15, 2023

Jan 08, 2024

Dec 14, 2023

División de acciones



Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos